Allay Therapeutics Completes Oversubscribed $60M Financing To Advance Ultra-Sustained Pain Platform

Sep 15, 2021•almost 4 years ago

Amount Raised

$60 Million

Menlo Park

Description

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures. Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC and WTT Investment Ltd. The proceeds from the Series C will advance the Company’s lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay’s platform for ultra-sustained analgesic products.

Company Information

Company

Allay Therapeutics

Location

Menlo Park, California, United States

About

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends